South African Assessment Pathway: Conformity Assessment and Essential Principles Evidence

1. Key takeaways

Under the Medical Devices Reliance Guideline (SAHPGL-MD-22 v1, 25 February 2026), SAHPRA review follows two pathways: products with an approval from a reference regulatory authority take the reliance pathway; products without a foreign approval — especially Class C and Class D devices — take the South African Assessment pathway. The latter requires conformity assessment evidence to support the review, and its core pillars are the ISO 13485 quality system certificate and a conformity assessment performed by an ISO 17021-accredited CAB. Reliance reduces duplicated review; South African assessment requires the company to complete the evidence chain itself.

The dividing line between the two pathways is the existence of a reference authority approval, and the workload difference between them is concentrated in the Essential Principles: under reliance, a foreign approval can serve as indirect evidence of conformity, whereas under South African assessment the company must argue conformity item by item on its own. The practical estimate for Class C and D devices without foreign approvals is that conformity assessment and clinical evidence preparation must start early, not after a call-up notice appears.

2. Legal basis

The table below lists the official sources relied upon.

3. Expert insights

Insight 1: Regulation 8(3)(d)(ii) is the statutory anchor of the South African Assessment pathway. The provision requires that, where applicable, a certified copy of a conformity assessment certificate issued by a Conformity Assessment Body (CAB) attesting that the device complies with the quality standards determined by SAHPRA be submitted. This provision writes third-party conformity assessment directly into the registration application requirements — it is not an optional enhancement but the necessary route when no foreign approval exists. Companies planning a South African Assessment file should treat the CAB engagement as a critical-path item, since audit scheduling, sampling and report issuance each carry their own lead time.

Insight 2: The Essential Principles are the substantive review standard of the South African Assessment pathway. Regulation 8(6) provides that a device submitted for registration must comply with the Essential Principles of safety and performance for medical devices, covering quality, safety and performance requirements. Under the reliance pathway, the foreign approval can serve as indirect evidence of Essential Principles conformity; under the South African Assessment pathway, the company must argue conformity item by item itself — the workload difference between the two routes is concentrated here. A clause-by-clause matrix against SAHPGL-MD-01 is the most efficient way to build and defend that argument.

Insight 3: Class C and Class D devices carry the main burden of the South African Assessment pathway. High-risk devices without a foreign approval have neither a reliance-ready review conclusion nor any relief from the strictest substantive review. The practical estimate is unambiguous: for these products, conformity assessment and clinical evidence preparation must be brought forward, rather than started only after a call-up notice is published. Because the highest-risk categories attract the deepest scrutiny, a deficiency discovered late in this pathway costs far more than the same deficiency discovered during internal preparation.

Insight 4: ISO 13485 and conformity assessment are two different things, and both are required. ISO 13485 demonstrates the system (at establishment level); conformity assessment demonstrates the product (at device level). A system certificate alone cannot substitute for product conformity assessment, and vice versa. Companies must manage these two lines separately in budget and scheduling: the certification audit addresses the organisation, while the conformity assessment addresses each device against SAHPRA’s determined quality standards. Combining the two in one plan without separating their deliverables is a common cause of late-stage discovery that a key document is missing.

Insight 5: Reliance and assessment can be combined. SAHPGL-MD-22 describes how reliance is used, while SAHPRA retains the right to request supplementary information. In practice the more common configuration is a hybrid: part of the file relies on foreign conclusions, while other parts — such as label localisation, local clinical data, or specific risk argumentation — are completed through South African local assessment. Companies should structure their dossiers so that modules can be swapped between reliance evidence and local evidence without rebuilding the whole submission, and should reserve a window for local supplementary information after filing.

4. Practical recommendations

The following actions align dossier strategy with the two pathways.

1. Determine the pathway first: the presence or absence of a reference authority approval is the first dividing line.
2. Without a foreign approval, start conformity assessment early: engage an ISO 17021-accredited CAB.
3. Run the system certificate and the product assessment in parallel: neither substitutes for the other.
4. Argue the Essential Principles clause by clause against SAHPGL-MD-01: build a point-by-point cross-reference matrix.
5. Prepare Class C and Class D products ahead of time: the highest-risk categories take longest under the assessment pathway.
6. Reserve a window for supplementary information after reliance: reliance does not exclude local follow-up questions.

5. Verification checklist

Confirm every item below before committing to a filing route.

• □ It has been determined whether the reliance pathway or the South African Assessment pathway applies
• □ The product classification has been confirmed (with Class C and Class D receiving particular attention)
• □ The ISO 13485 system certificate is ready or has been scheduled
• □ An ISO 17021-accredited CAB has been engaged for product conformity assessment
• □ A certified copy of the conformity assessment certificate has been prepared per Regulation 8(3)(d)(ii)
• □ A clause-by-clause Essential Principles matrix has been built per SAHPGL-MD-01
• □ System evidence and product evidence are managed separately
• □ A window for local supplementary information after reliance has been reserved

Regulatory information verified as of 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the official sources listed in the legal basis section above, as published on that date. Where official documents are subsequently updated, the latest published version prevails.

• South Africa local resources: GRZAN assists manufacturers from the Chinese mainland and overseas with SAHPRA medical device Establishment Licence (MDEL) applications and product registration preparation, including Authorised Representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and adverse event reporting mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A/B/C/D), establishment licence application and renewal, reliance pathway justification, technical documentation and Essential Principles conformity argumentation, labelling and instructions-for-use localisation (English), and post-market vigilance and annual compliance information submission support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.